Inspiryl Turbuhaler (salbutamol dry-powder inhaler) / AstraZeneca - LARVOL DELTA

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients (clinicaltrials.gov) - P4; N=871; Active, not recruiting; Sponsor: AstraZeneca; Trial completion date: Jan 2022 ➔ May 2022; Trial primary completion date: Jan 2022 ➔ May 2022

Clinical • Trial completion date • Trial primary completion date • Asthma • Immunology • Inflammation • Respiratory Diseases

SHAMAL: A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab (clinicaltrials.gov) - P4; N=240; Recruiting; Sponsor: AstraZeneca; N=871 ➔ 240

Clinical • Enrollment change • Asthma • Immunology • Respiratory Diseases

SHAMAL: A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab (clinicaltrials.gov) - P4; N=871; Recruiting; Sponsor: AstraZeneca; N=237 ➔ 871; Trial completion date: Apr 2022 ➔ Jul 2022; Trial primary completion date: Apr 2022 ➔ Jul 2022

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Asthma • Respiratory Diseases

SHAMAL: A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab (clinicaltrials.gov) - P4; N=237; Recruiting; Sponsor: AstraZeneca; N=871 ➔ 237

Clinical • Enrollment change • Asthma • Respiratory Diseases

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients (clinicaltrials.gov) - P4; N=871; Active, not recruiting; Sponsor: AstraZeneca; N=80 ➔ 871

Clinical • Enrollment change • Asthma • Immunology • Respiratory Diseases

SHAMAL: A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab (clinicaltrials.gov) - P4; N=871; Recruiting; Sponsor: AstraZeneca; Not yet recruiting ➔ Recruiting; N=200 ➔ 871; Trial completion date: Oct 2021 ➔ Apr 2022; Trial primary completion date: Oct 2021 ➔ Apr 2022

Clinical • Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Asthma • Respiratory Diseases

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients (clinicaltrials.gov) - P4; N=80; Active, not recruiting; Sponsor: AstraZeneca; Trial completion date: Sep 2021 ➔ Dec 2021; Trial primary completion date: Sep 2021 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Asthma • Immunology • Respiratory Diseases

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients (clinicaltrials.gov) - P4; N=80; Active, not recruiting; Sponsor: AstraZeneca; Recruiting ➔ Active, not recruiting; Trial completion date: Mar 2021 ➔ Sep 2021

Enrollment closed • Trial completion date

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab (clinicaltrials.gov) - P4; N=200; Not yet recruiting; Sponsor: AstraZeneca

Clinical • New P4 trial

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients (clinicaltrials.gov) - P4; N=80; Recruiting; Sponsor: AstraZeneca; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients (clinicaltrials.gov) - P4; N=80; Not yet recruiting; Sponsor: AstraZeneca

Clinical • New P4 trial